LeMaitre Vascular Inc (NASDAQ:LMAT) Shares Bought by Morgan Stanley

Morgan Stanley raised its holdings in LeMaitre Vascular Inc (NASDAQ:LMAT) by 151.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 202,672 shares of the medical instruments supplier’s stock after acquiring an additional 122,152 shares during the period. Morgan Stanley owned approximately 1.02% of LeMaitre Vascular worth $5,671,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Swiss National Bank raised its holdings in LeMaitre Vascular by 2.3% in the 2nd quarter. Swiss National Bank now owns 31,000 shares of the medical instruments supplier’s stock valued at $867,000 after acquiring an additional 700 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of LeMaitre Vascular by 3.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 262,851 shares of the medical instruments supplier’s stock worth $7,355,000 after buying an additional 8,942 shares during the last quarter. Conestoga Capital Advisors LLC increased its holdings in shares of LeMaitre Vascular by 2.5% during the 2nd quarter. Conestoga Capital Advisors LLC now owns 1,741,196 shares of the medical instruments supplier’s stock worth $48,719,000 after buying an additional 42,315 shares during the last quarter. Marshall Wace North America L.P. increased its holdings in shares of LeMaitre Vascular by 33.6% during the 2nd quarter. Marshall Wace North America L.P. now owns 55,278 shares of the medical instruments supplier’s stock worth $1,546,000 after buying an additional 13,916 shares during the last quarter. Finally, Copeland Capital Management LLC increased its holdings in shares of LeMaitre Vascular by 150.7% during the 2nd quarter. Copeland Capital Management LLC now owns 386,557 shares of the medical instruments supplier’s stock worth $10,816,000 after buying an additional 232,351 shares during the last quarter. Institutional investors own 78.60% of the company’s stock.

Shares of NASDAQ LMAT opened at $35.62 on Tuesday. The company has a 50 day simple moving average of $33.37 and a 200-day simple moving average of $30.09. The company has a market capitalization of $695.64 million, a P/E ratio of 42.40, a P/E/G ratio of 4.08 and a beta of 1.22. LeMaitre Vascular Inc has a 1 year low of $21.79 and a 1 year high of $36.06.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Wednesday, July 24th. The medical instruments supplier reported $0.23 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.02. The business had revenue of $29.48 million during the quarter, compared to the consensus estimate of $28.90 million. LeMaitre Vascular had a net margin of 16.72% and a return on equity of 13.15%. The business’s revenue was up 9.1% compared to the same quarter last year. During the same quarter last year, the firm earned $0.43 EPS. As a group, equities research analysts forecast that LeMaitre Vascular Inc will post 0.86 earnings per share for the current fiscal year.

A number of analysts have recently issued reports on LMAT shares. Zacks Investment Research downgraded shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 25th. BidaskClub upgraded shares of LeMaitre Vascular from a “buy” rating to a “strong-buy” rating in a report on Friday, September 13th. ValuEngine downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Monday, October 7th. First Analysis upgraded shares of LeMaitre Vascular from an “outperform” rating to a “strong-buy” rating and set a $37.00 price target for the company in a report on Monday, October 14th. Finally, Lake Street Capital raised their price target on shares of LeMaitre Vascular from $27.00 to $34.00 and gave the stock a “hold” rating in a report on Thursday, July 25th. Four research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company’s stock. LeMaitre Vascular presently has an average rating of “Buy” and an average price target of $36.50.

In related news, Chairman George W. Lemaitre sold 66,037 shares of the stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $34.45, for a total transaction of $2,274,974.65. Following the completion of the transaction, the chairman now owns 3,171,124 shares of the company’s stock, valued at approximately $109,245,221.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Lawrence J. Jasinski sold 5,000 shares of the stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $32.00, for a total transaction of $160,000.00. Following the transaction, the director now directly owns 10,833 shares of the company’s stock, valued at approximately $346,656. The disclosure for this sale can be found here. Insiders have sold a total of 129,654 shares of company stock valued at $4,423,865 in the last ninety days. 19.60% of the stock is currently owned by corporate insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Featured Story: Net Margin

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular Inc (NASDAQ:LMAT).

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.